Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Comput Intell Neurosci ; 2022: 4756390, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36465955

RESUMEN

In order to solve the problems of restricted classroom and lack of repeated training in good curriculum, the design and development of a school life adaptation curriculum based on VR is proposed. This study identified six life adaptation themes for design and development (recognizing facial expressions, crossing the road, how to get lost, shopping, taking public transport, and job interview) and set the objectives, design principles, specific content, teaching evaluation, and other aspects of virtual reality life adaptation course. Combined with the characteristics of virtual reality, the implementation suggestions and matters needing attention are put forward. The results showed that, in the recognition of human facial expressions, 51 experts thought it was appropriate, 3 experts thought it needed to be modified, and no expert thought it was inappropriate. On the topic of crossing the road, 46 experts thought it was appropriate, eight thought it needed to be modified, and no expert thought it was inappropriate. On the theme of taking public transportation, 48 experts thought it was appropriate, 6 experts thought it needed to be modified, and no expert thought it was inappropriate. For the three major topics of how to get lost, shopping, and job interview, 2-3 experts put forward different opinions and think that the topic is not appropriate mainly because the grade arrangement is not appropriate. Conclusion. The VR-based curriculum for school life adaptation has been reviewed by experts and revised by researchers. It is scientific, interesting, and operable, solves the teaching problems of life adaptation teachers, and provides a safe, reliable, and effective practice channel for students.


Asunto(s)
Inteligencia Artificial , Realidad Virtual , Humanos , Tecnología , Instituciones Académicas , Programas Informáticos
2.
Neuropharmacology ; 196: 108685, 2021 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-34175325

RESUMEN

Targeting the common molecular mechanism of type 2 diabetes mellitus and Alzheimer's disease (AD), including dysregulation of glucose metabolism, insulin resistance, and neuroinflammation, might be an efficient treatment strategy for AD. Previous studies have shown that 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), an endogenous PPARγ agonist, has anti-inflammatory, insulin sensitizing and anti-diabetic effects. However, whether 15d-PGJ2 has beneficial effects on AD remains to be elucidated. In the present study, we found that intranasal administration of 15d-PGJ2 (300 ng/30 µL/day) for 3 months significantly inhibited Aß plaques, suppressed neuroinflammation, and attenuated cognitive deficits in APP/PS1 transgenic mice. Interestingly, 15d-PGJ2 treatment could increase brain glucose uptake, as detected by 18F-FDG microPET imaging, and co-localization of GLUT4 and NeuN in the hippocampus of APP/PS1 mice. Furthermore, 15d-PGJ2 markedly increased the expression of PPARγ and PGC-1α, upregulated GLUT4, and decreased the phosphorylation of IRS-1 (Ser616) in the hippocampus of APP/PS1 mice. Importantly, co-administration of a PPARγ antagonist GW9662 abrogated these protective effects of 15d-PGJ2. Collectively, intranasal 15d-PGJ2 conferred protective effects against AD by activating PPARγ-dependent PGC-1α/GLUT4 signalling. The PPARγ agonist 15d-PGJ2 might be a potential therapeutic drug for AD.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Encéfalo/efectos de los fármacos , Glucosa/metabolismo , Factores Inmunológicos/farmacología , Neuronas/efectos de los fármacos , PPAR gamma/efectos de los fármacos , Prostaglandina D2/análogos & derivados , Administración Intranasal , Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/efectos de los fármacos , Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/genética , Anilidas/farmacología , Animales , Conducta Animal/efectos de los fármacos , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Citocinas/efectos de los fármacos , Citocinas/metabolismo , Fluorodesoxiglucosa F18 , Transportador de Glucosa de Tipo 4/efectos de los fármacos , Transportador de Glucosa de Tipo 4/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Ratones , Ratones Transgénicos , Prueba del Laberinto Acuático de Morris , Neuronas/metabolismo , PPAR gamma/antagonistas & inhibidores , PPAR gamma/metabolismo , Fragmentos de Péptidos/efectos de los fármacos , Fragmentos de Péptidos/metabolismo , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/efectos de los fármacos , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma/metabolismo , Tomografía de Emisión de Positrones , Presenilina-1/genética , Prostaglandina D2/farmacología , Radiofármacos , Transducción de Señal
3.
Phytomedicine ; 82: 153434, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-33529962

RESUMEN

BACKGROUND: Glioblastoma multiforme (GBM) is the most frequent, lethal and aggressive tumour of the central nervous system in adults. The discovery of novel anti-GBM agents based on the isocitrate dehydrogenase (IDH) mutant phenotypes and classifications have attracted comprehensive attention. PURPOSE: Diterpenoids are a class of naturally occurring 20-carbon isoprenoid compounds, and have previously been shown to possess high cytotoxicity for a variety of human tumours in many scientific reports. In the present study, 31 cassane diterpenoids of four types, namely, butanolide lactone cassane diterpenoids (I) (1-10), tricyclic cassane diterpenoids (II) (11-15), polyoxybutanolide lactone cassane diterpenoids (III) (16-23), and fused furan ring cassane diterpenoids (IV) (24-31), were tested for their anti-glioblastoma activity and mechanism underlying based on IDH1 mutant phenotypes of primary GBM cell cultures and human oligodendroglioma (HOG) cell lines. RESULTS: We confirmed that tricyclic-type (II) and compound 13 (Caesalpin A, CSA) showed the best anti-neoplastic potencies in IDH1 mutant glioma cells compared with the other types and compounds. Furthermore, the structure-relationship analysis indicated that the carbonyl group at C-12 and an α, ß-unsaturated ketone unit fundamentally contributed to enhancing the anti-glioma activity. Studies investigating the mechanism demonstrated that CSA induced oxidative stress via causing glutathione reduction and NOS activation by negatively regulating glutaminase (GLS), which proved to be highly dependent on IDH mutant type glioblastoma. Finally, GLS overexpression reversed the CSA-induced anti-glioma effects in vitro and in vivo, which indicated that the reduction of GLS contributed to the CSA-induced proliferation inhibition and apoptosis in HOG-IDH1-mu cells. CONCLUSION: Therefore, the present results demonstrated that compared with other diterpenoids, tricyclic-type diterpenoids could be a targeted drug candidate for the treatment of secondary IDH1 mutant type glioblastoma through negatively regulating GLS.


Asunto(s)
Apoptosis/efectos de los fármacos , Neoplasias Encefálicas/patología , Diterpenos/farmacología , Glioblastoma/patología , Glutaminasa/antagonistas & inhibidores , Isocitrato Deshidrogenasa/genética , Mutación , Línea Celular Tumoral , Humanos , Estrés Oxidativo
4.
Phytother Res ; 33(6): 1736-1747, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31006910

RESUMEN

Glioblastoma multiforme (GBM) is a highly aggressive type of brain tumour. Patients with GBM respond poorly to chemotherapy and have poor survival outcomes. Neuron-glial antigen 2 (NG2), also known as chondroitin sulphate proteoglycan 4 (CSPG4), has been shown to contribute to critical processes, such as cell survival, proliferation, and chemotherapy resistance, during glioma progression. In this study, we found that furanodienone (FUR), a diene-type sesquiterpene isolated from the rhizomes of Rhizoma curcumae, exhibited a potential cytotoxic effect on temozolomide (TMZ)-resistant GBM cells in vitro by inhibiting CSPG4 and related signalling pathways. Studies investigating the mechanism demonstrated that FUR suppressed CSPG4-Akt-ERK signalling, inflammatory responses, and cytokine levels but activated caspase-dependent pathways and mitochondrial dysfunction. Furthermore, an immunofluorescence assay and a dual-luciferase reporter assay revealed that inhibition of EGR1-mediated transcription might have contributed to the FUR-dependent blockade of CSPG4 signalling and glioma cell survival. These results established a link between FUR-induced CSPG4 inhibition and the suppression of EGR1-dependent transcription. Attenuation of ERK1/2 and cytokine signalling might have generated the EGR1-dependent negative feedback loop of the CSPG4 pathway during FUR-induced apoptosis. These findings suggested that FUR could be a therapeutic candidate for the treatment of malignant glioma via targeting CSPG4 signalling.


Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Resistencia a Antineoplásicos/efectos de los fármacos , Proteína 1 de la Respuesta de Crecimiento Precoz/fisiología , Furanos/farmacología , Glioblastoma/tratamiento farmacológico , Sesquiterpenos/farmacología , Temozolomida/uso terapéutico , Adulto , Apoptosis/efectos de los fármacos , Apoptosis/genética , Neoplasias Encefálicas/genética , Neoplasias Encefálicas/patología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Proteoglicanos Tipo Condroitín Sulfato/genética , Proteoglicanos Tipo Condroitín Sulfato/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/genética , Resistencia a Antineoplásicos/genética , Furanos/administración & dosificación , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Glioblastoma/genética , Glioblastoma/patología , Humanos , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Sesquiterpenos/administración & dosificación , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Temozolomida/administración & dosificación , Transcripción Genética/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA